Targeting HMGCS2: Ketogenesis Suppression Accelerates NAFLD Progression in T2DM Comorbidity, While Cynaroside Ameliorates NASH in Concomitant T2DM. Here, HMGCS2 is linked to metabolic dysfunction-associated steatohepatitis.